These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 8873215)

  • 1. Role of CYP1A2 in caffeine pharmacokinetics and metabolism: studies using mice deficient in CYP1A2.
    Buters JT; Tang BK; Pineau T; Gelboin HV; Kimura S; Gonzalez FJ
    Pharmacogenetics; 1996 Aug; 6(4):291-6. PubMed ID: 8873215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Theophylline pharmacokinetics: comparison of Cyp1a1(-/-) and Cyp1a2(-/-) knockout mice, humanized hCYP1A1_1A2 knock-in mice lacking either the mouse Cyp1a1 or Cyp1a2 gene, and Cyp1(+/+) wild-type mice.
    Derkenne S; Curran CP; Shertzer HG; Dalton TP; Dragin N; Nebert DW
    Pharmacogenet Genomics; 2005 Jul; 15(7):503-11. PubMed ID: 15970798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the aqueous extract from Salvia miltiorrhiza Bunge on caffeine pharmacokinetics and liver microsomal CYP1A2 activity in humans and rats.
    Wang X; Yeung JH
    J Pharm Pharmacol; 2010 Aug; 62(8):1077-83. PubMed ID: 20663043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic clearance and demethylation of caffeine in sheep and cattle.
    Danielson TJ; Golsteyn LR
    Drug Metab Dispos; 1996 Oct; 24(10):1058-61. PubMed ID: 8894505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in caffeine and paraxanthine metabolism between human and murine CYP1A2.
    Labedzki A; Buters J; Jabrane W; Fuhr U
    Biochem Pharmacol; 2002 Jun; 63(12):2159-67. PubMed ID: 12110375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurement of CYP1A2 activity: a focus on caffeine as a probe.
    Perera V; Gross AS; McLachlan AJ
    Curr Drug Metab; 2012 Jun; 13(5):667-78. PubMed ID: 22554278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Theophylline has no advantages over caffeine as a putative model drug for assessing CYPIA2 activity in humans.
    Rasmussen BB; Brøsen K
    Br J Clin Pharmacol; 1997 Mar; 43(3):253-8. PubMed ID: 9088579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clozapine pharmacokinetics and pharmacodynamics studied with Cyp1A2-null mice.
    Aitchison KJ; Jann MW; Zhao JH; Sakai T; Zaher H; Wolff K; Collier DA; Kerwin RW; Gonzalez FJ
    J Psychopharmacol; 2000; 14(4):353-9. PubMed ID: 11198052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A fluvoxamine-caffeine interaction study.
    Jeppesen U; Loft S; Poulsen HE; Brśen K
    Pharmacogenetics; 1996 Jun; 6(3):213-22. PubMed ID: 8807660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans.
    Rasmussen BB; Brøsen K
    Ther Drug Monit; 1996 Jun; 18(3):254-62. PubMed ID: 8738764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations.
    Fuhr U; Rost KL; Engelhardt R; Sachs M; Liermann D; Belloc C; Beaune P; Janezic S; Grant D; Meyer UA; Staib AH
    Pharmacogenetics; 1996 Apr; 6(2):159-76. PubMed ID: 9156694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Xanthine oxidase inhibition by allopurinol affects the reliability of urinary caffeine metabolic ratios as markers for N-acetyltransferase 2 and CYP1A2 activities.
    Fuchs P; Haefeli WE; Ledermann HR; Wenk M
    Eur J Clin Pharmacol; 1999 Jan; 54(11):869-76. PubMed ID: 10027663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of venlafaxine on CYP1A2-dependent pharmacokinetics and metabolism of caffeine.
    Amchin J; Zarycranski W; Taylor KP; Albano D; Klockowski PM
    J Clin Pharmacol; 1999 Mar; 39(3):252-9. PubMed ID: 10073324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of age and smoking on in vivo CYP1A2, flavin-containing monooxygenase, and xanthine oxidase activities in Koreans: determination by caffeine metabolism.
    Chung WG; Kang JH; Park CS; Cho MH; Cha YN
    Clin Pharmacol Ther; 2000 Mar; 67(3):258-66. PubMed ID: 10741629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2.
    Kinzig-Schippers M; Fuhr U; Zaigler M; Dammeyer J; Rüsing G; Labedzki A; Bulitta J; Sörgel F
    Clin Pharmacol Ther; 1999 Mar; 65(3):262-74. PubMed ID: 10096258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics.
    Perera V; Gross AS; Xu H; McLachlan AJ
    J Pharm Pharmacol; 2011 Sep; 63(9):1161-8. PubMed ID: 21827488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of major tanshinones isolated from Danshen (Salvia miltiorrhiza) on rat CYP1A2 expression and metabolism of model CYP1A2 probe substrates.
    Wang X; Lee WY; Or PM; Yeung JH
    Phytomedicine; 2009 Aug; 16(8):712-25. PubMed ID: 19403289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of cytochrome P450 (CYP) 1A2 activity using caffeine phenotyping and olanzapine disposition in healthy volunteers.
    Shirley KL; Hon YY; Penzak SR; Lam YW; Spratlin V; Jann MW
    Neuropsychopharmacology; 2003 May; 28(5):961-6. PubMed ID: 12644842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plant polyphenol curcumin significantly affects CYP1A2 and CYP2A6 activity in healthy, male Chinese volunteers.
    Chen Y; Liu WH; Chen BL; Fan L; Han Y; Wang G; Hu DL; Tan ZR; Zhou G; Cao S; Zhou HH
    Ann Pharmacother; 2010 Jun; 44(6):1038-45. PubMed ID: 20484172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assays for CYP1A2 by testing in vivo metabolism of caffeine in humans.
    Tang BK; Kalow W
    Methods Enzymol; 1996; 272():124-31. PubMed ID: 8791769
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.